In the SURMOUNT-1 trial, tirzepatide demonstrated substantial weight loss of 16.5% to 22.4% over 72 weeks in people without diabetes
The CDC and clinical guidelines suggest that expecting 12 pounds weekly during the initial phase and 0.51 pound weekly during later phases represents a reasonable framework, though week-to-week fluctuations due to fluid retention, menstrual cycles, or dietary sodium intake are normal and should not cause alarm
This improved comfort may be related to: More balanced hormonal signaling (GLP-1 + GIP) GIP activity that may reduce GLP-1-related nausea Smoother appetite regulation at equivalent weight-loss levels Personalized dosing and slow titration are essential for both medications
Dunn WB, Broadhurst D, Begley P, et al
Patients at our center receive personalized counseling to help them adopt balanced eating habitsfocusing on whole grains, lean proteins, fruits, vegetables, and healthy fats, while reducing processed foods, added sugars, and saturated fats